The average walker takes about 10,000 steps per day, which can put tremendous stress on the 26 bones and 33 joints in your feet. The Look for the “O” campaign from the American Orthopaedic Foot & Ankle Society (AOFAS) encourages consumers to take charge of their foot and ankle health and choose a foot and ankle orthopaedic surgeon when medical care is needed.
“Most people don’t give much thought to their foot health – that is, until something goes wrong,” stated J. Chris Coetzee, MD, president of the AOFAS Board of Directors. “But 75% of all people experience foot pain at some point in their lives, and it’s important to know how to find the best medical care before a problem arises.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8164351-aofas-what-is-a-foot-and-ankle-orthopaedic-surgeon/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Noted pediatric heart surgeon Dr. Kristine Guleserian has opened up her OR, and her career to author Mark Oristano to create Surgeon’s Story Inside OR 6 With a top Pediatric Heart Surgeon. Dr. Guleserian’s life, training and work are discussed in detail, framed around the incredibly dramatic story of a heart transplant operation for a two-year old girl whose own heart was rapidly dying. Find out more at- http://surgeonsstory.com/ Media Contact: For a review copy of Surgeon’s Story or to schedule an interviewwith Mark Oristano, contact Scott Lorenz of Westwind Communications Book Marketing, 734 667 2090 scottlorenz@westwindcos.com or http://www.book-marketing-expert.com Medical Non-Fiction
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
With September marking National Prostate Cancer Awareness Month and the kick-off of the 2015 NFL season, the Urology Care Foundation and the NFL have renewed their commitment to driving prostate health awareness, as well as teamed up to highlight a Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to take charge of their health through the Know Your Stats® campaign.
The Know Your Stats® campaign is a rallying force to connect, educate and inspire men across the country to know their prostate cancer risk and talk to their doctor about whether prostate cancer testing is right for them.
“It is important for men to know their risk and talk to their doctors so they can determine if prostate cancer testing is right for them,” said Richard A. Memo, MD, Chair of the Urology Care Foundation. “Having the tools and facts empowers individuals and their doctors to make informed decisions.”
Prostate cancer is the second most common cancer in America, affecting one in seven men. Odds increase to one in five if they are African American and one in three if they have a family history; however, the educational tools are making an impact. More men are talking with their doctors and getting tested, and fewer men are dying from the disease.
To view the multimedia release go to:
http://www.multivu.com/players/English/7365551-prostate-cancer-know-your-stats-psa/
The latest edition of the Boeing Store Custom Hangar catalog – featuring a collection of furniture and artwork derived from genuine aircraft parts -- is now available. Offerings include a bench made from a 727-200 jetliner wing slat; a B-17 Flying Fortress propeller blade; and a sleek bar made from the engine of a DC-9/MD-80 airliner.
Buyers and craftspeople for the Custom Hangar climb through aviation boneyards and storage facilities in search of rare artifacts that they refurbish and finish by hand. Each piece is placed in a museum-quality mounting fabricated using authentic materials such as aviation-grade aluminum, steel, and titanium.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903151-boeing-store-custom-hangar-catalog/
The following statement is being issued by Block & Leviton LLP, Finkelstein Thompson LLP and Green & Noblin PC regarding the Drywall Antitrust Litigation.
If you purchased Wallboard INDIRECTLY from one or more of the companies listed below, your rights may be affected by proposed Settlements
Proposed class settlements totaling $10.5 million have been reached with two Defendants in In re Domestic Drywall Antitrust Litigation, MDL No. 2437 and 13-MD-2437, pending in the U.S. District Court for the Eastern District of Pennsylvania.
If you purchased for end use wallboard manufactured and/or distributed by CertainTeed Gypsum, Inc., USG Corporation, United States Gypsum Company, New NGC, Inc., Lafarge North America, Inc., Eagle Materials, Inc., American Gypsum Company LLC, PABCO Building Products, LLC, TIN, Inc., or their subsidiaries (collectively, the “Defendants”), between January 1, 2012 and November 30, 2014, you may be a class member. “Wallboard” means paper-backed gypsum wallboard, also called drywall or plasterboard.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449651-drywall-class-action-settlement/
DEWALT® Charlotte, NC manufacturing plant celebrated a significant milestone this past week, as the professional tool brand’s 10-millionth tool rolled off the production line. Company executives were on hand to build the 10-millionth tool – a 20V MAX* XR Lithium Ion Brushless 3-Speed Hammer Drill (DCD996P2).
Across its seven U.S. manufacturing plants, the brand produced more than 90 million individual products Made in the USA with global materials in 2016, an almost 50 percent increase from the 62 million individual products in 2015, just one year earlier. This is a meaningful accomplishment towards the brand’s effort to expand its domestic manufacturing using global materials, an effort that began in 2013. In addition to Charlotte, DEWALT operates manufacturing facilities in New Britain, CT; Greenfield, IN; Hampstead, MD; Shelbyville, KY; Cheraw, SC; and Jackson, TN.
To view the multimedia release go to:
https://www.multivu.com/players/English/8005956-dewalt-10-millionth-tool/
Dr. Maurice Rawlings, MD, a heart surgeon, has written a number of books on the near-death experience and clearly shows from his own practice and the experiences of his patients, that not everyone goes to the light when they die, where there is total love. He has written of many patients being resuscitated on the operating table and speaking about being in hell, where there was a real devil and demons, and where the inhabitants were tormented with fire. Dr. Rawlings writes that these people are a lot more reluctant to talk about it than those who went to the good place. DivineRevelations.info
A recently published scientific study from Lund University by lead researcher Charlotte Erlanson-Albertsson, MD, PhD found that subjects who were trying to lose weight and used the patented spinach extract Appethyl on a daily basis lost 43 percent more weight compared to those ingesting a placebo.
In this clinical trial, overweight women were given either a daily five gram dose of Appethyl or a control drink immediately before breakfast. Researchers found that the weight of the women ingesting Appethyl decreased significantly at 43 percent more than subjects ingesting the control drink.
This is one of three studies that also compared the effects of Appethyl after 90 days with those found after the first dose and found no decline of effects, indicating that Appethyl takes effect after the first dose and is just as effective after long-term use. One study showed that Appethyl reduced hunger by 25 percent four hours after consumption, in addition to reducing thoughts about food by 33 percent.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7426951-appethyl-spinach-extract/
